Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1708-8305.2009.00362.x | DOI Listing |
BMJ Open
January 2025
IMA World Health, Kinshasa, Democratic Republic of the Congo.
Objectives: To understand the current state of maternal, newborn and child health (MNCH) among internally displaced persons (IDPs), returnees and host communities in remote counties of Jonglei state.
Design: Cross-sectional, randomly sampled, mixed-methods, population-based household study.
Setting: Ayod, Nyirol, Fangak and Pigi counties of Jonglei, South Sudan.
Mult Scler
January 2025
Department of Neurology, St. Josef-Hospital, Katholisches Klinikum Bochum, Ruhr-University Bochum, Bochum, Germany.
Background: In Europe, ofatumumab is approved for breastfeeding, but data on its transfer into breast milk and clinical experience are lacking.
Objective: To analyze (1) health, development, and adverse events after live vaccination of ofatumumab-exposed breastfed infants and (2) detectability of ofatumumab in breast milk, and to calculate the relative infant dose (RID) using two methods, the traditional method and a second method considering maternal exposure to multiple ofatumumab doses and extended collection period.
Methods: In this observational study, clinical data were collected by standardized telephone interviews up to 2 years postpartum.
Neurol Neuroimmunol Neuroinflamm
January 2025
Katholisches Klinikum Bochum, St. Josef Hospital, Bochum, Germany.
Background And Objectives: Ocrelizumab labeling advises contraception for women during treatment and for 6-12 months thereafter. Because pregnancies may occur during this time, it is critical to understand pregnancy and infant outcomes in women with multiple sclerosis (MS) after ocrelizumab exposure.
Methods: Pregnancy cases reported to Roche global pharmacovigilance until 12 July 2023 were analyzed.
Food Microbiol
March 2025
School of Biological Sciences and Institute for Global Food Security, Queen's University Belfast, UK. Electronic address:
When maternal milk is unavailable, donor human milk (DHM) from human milk banks (HMBs) is the optimal alternative, as recommended by the World Health Organisation. The microbiota of DHM could contain opportunistic pathogens, which means rigorous microbiological screening for DHM, prior to pasteurisation, is recommended to safeguard recipients. Here, an analysis of 6863 DHM samples from 1419 donors at the Hearts Milk Bank between 2017 and 2023 showed approximately 70.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!